Hutchison China Meditech Ltd (HCM)
HCM Share PerformanceMore
|52 week high||5,920.00 09/01/18|
|52 week low||2,840.00 19/04/17|
|52 week change||1,770.00 (57.84%)|
|4 week volume||353,104 22/02/18|
Latest News« previous» nextMore
20/03/2018 - 09:15 RNS
RNS Number: 2681I Hutchison China Meditech Limited 20 March 2018 Grant of Share Options under Share Option Scheme London: Tuesday, March 20, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 19, 2018 , it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Me...
19/03/2018 - 07:10 RNS
RNS Number: 0984I Hutchison China Meditech Limited 19 March 2018 Director's Share Dealing London: Monday, March 19 , 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company ("ADSs", each representi...
12/03/2018 - 11:22 RNS
RNS Number: 4144H Hutchison China Meditech Limited 12 March 2018 Press release Publication of Form 20-F London: Monday, March 12, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2017. This is available for viewing at http://www.rns-pdf.londonstockexchange....
12/03/2018 - 07:02 RNS
RNS Number: 3706H Hutchison China Meditech Limited 12 March 2018 Hutchison China MediTech Limited (Chi-Med) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results i n line with guidance Group r evenue up 12 % to $ 2 41.2 million (201 6: $ 216.1 m); N et loss attr...
06/03/2018 - 07:00 RNS
RNS Number: 7968G Hutchison China Meditech Limited 06 March 2018 Press Release Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China London: Tuesday , March 6 , 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients w...
13/02/2018 - 09:41 StockMarketWire
Hutchison China MediTech Limited said it completed the enrollment of 527 patients in pivotal phase III faluca trial with fr...
13/02/2018 - 07:01 RNS
RNS Number: 7097E Hutchison China Meditech Limited 13 February 2018 Press Release Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer London: Tuesday, February 13, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA , its Ph...
05/02/2018 - 07:00 RNS
RNS Number: 7593D Hutchison China Meditech Limited 05 February 2018 Chi-Med to Announce 2017 Final Results London: Monday , February 5, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). A...
Latest discussion posts More
“Director Buys always very welcome!”▼
“sporty, only that we will book net income of $20-$35m on sales of $110m - $160m with 20-25% penetration rate And to my mind that could translate into $2450 mcap uplift or ...”▼
“Bernie, our CEO actually said it during the Analyst Presentation, he hopes they don't take up the rights because we now have or will soon have the capabilities to take it ...”▼
Codes & Symbols
|Symbols||HCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM|